The safety and efficacy of ofloxacin, 400 mg orally, were compared with those of amoxicillin, 3.0 g, plus probenecid, 1 
Neisseria gonorrhoeae has shown a remarkable propensity for developing resistance to a variety of useful antibiotics, such as penicillin, tetracycline, and spectinomycin, by several different mechanisms (4, 5, 12) . Penicillinase-producing N. gonorrhoeae (PPNG) now accounts for more than 2% of all reported gonococcal infections in the United States (2) . The increasing prevalence of and difficulty in screening for gonococci with plasmid-mediated tetracycline resistance (TRNG) (12) and strains with chromosomally-mediated resistance to penicillin and tetracycline (CMRNG) (5) have also complicated therapy. Tetracycline is no longer recommended by the Centers for Disease Control or the U.S. Public Health Service as sole therapy for gonorrhea, and treatment with the penicillins is inappropriate in some geographic areas (3) . Ceftriaxone is currently the drug of choice for treatment in areas where there is a high prevalence of antibiotic-resistant gonococcal strains (3), but it must be administered intramuscularly and is relatively expensive. Ceftriaxone-resistant gonococci have yet to be discovered, but incremental decreases in susceptibility among gonococci to ceftriaxone have been reported (2) . These problems underscore the need for continued development of safe, inexpensive, reliable, and easily administered alternative treatments for gonococcal infection, including infection at rectal and pharyngeal sites.
Ofloxacin is a synthetic carboxyquinolone antibiotic with potent bactericidal activity against a broad spectrum of gram-positive and gram-negative bacteria, including N. gon- ,ug/ml) (14) . Although levels of genital ofloxacin have not been studied, concentrations in plasma should exceed the MIC90 for N. gonorrhoeae for 36 to 48 h after a single 400-mg dose (11; Ortho Pharmaceuticals, unpublished data). This multicenter, randomized study was performed to compare the safety and efficacy of ofloxacin, 400 mg orally, with that of amoxicillin, 3.0 g, plus probenecid, 1.0 g orally, as single-dose therapy for men and women with uncomplicated gonococcal infection.
MATERIALS AND METHODS
Patient population. Men and nonpregnant, nonnursing women between the ages of 18 and 65 who attended sexually transmitted diseases clinics in Indianapolis, Ind.; Baltimore, Md.; Seattle, Wash.; and Tacoma, Wash., between July 1986 and June 1987 were invited to participate in the study. Men and women were eligible if Gram stain of urethral or cervical exudate contained gram-negative intracellular diplococci. Women were also eligible if a recent screening culture had grown N. gonorrhoeae or if contact with a man with gonorrhea within the last thirty days was documented. Patients were excluded from the study if they had (i) a history of allergy to penicillins, quinolones, or probenecid; (ii) clinical evidence for complicated gonococcal infection (pelvic inflammatory disease, epididymitis, or disseminated gonococcal infection); (iii) known syphilis or infection with Chlamydia trachomatis; or (iv) therapy with antibiotics with activity against N. gonorrhoeae within the previous 14 days. The sexual orientation of each patient and the number of previous sexually transmitted diseases were recorded on the basis of self-reported history.
Study design and treatment. Patients were treated with ofloxacin, 400 mg orally, or amoxicillin, 3 g, plus probenecid, 1 g orally, according to open preassigned randomization schedules. A medical history, directed physical examination, cultures of exposed sites, and blood and urine tests for toxicity screening were obtained before treatment. Patients were instructed to refrain from sexual activity until after the follow-up visit, 6 to 9 days later. All patients who failed initial therapy were treated with ceftriaxone, 250 mg intramuscularly. All patients were treated for the possibility of concomitant infection with C. trachomatis at the conclusion of the study.
Isolation of N. gonorrhoeae and C. trachomatis. Urethral cultures for N. gonorrhoeae and C. trachomatis were obtained from all male patients by inserting a calcium alginate swab 2 to 4 cm beyond the urethral meatus. Endocervical cultures for both organisms were obtained from all female patients with cotton-tipped swabs. Pharyngeal and rectal cultures were obtained if indicated by a history of sexual exposure. At the follow-up visit, 6 to 9 days after treatment cervical and rectal cultures for N. gonorrhoeae and cervical cultures for C. trachomatis were obtained from all female patients, and urethral cultures for both organisms were obtained from all male patients for the test of cure. Additional cultures were obtained at the follow-up visit from any other sites that were infected initially.
Specimens for gonococcal culture were inoculated immediately onto modified Thayer-Martin medium and incubated at 35°C in candle extinction jars. N. gonorrhoeae was identified presumptively by colonial morphology, oxidase reaction, and Gram stain. Presumptive identification was confirmed by using fluorescein-conjugated monoclonal antibodies (Syva Corp., Palo Alto, Calif.) (10), Gonochek II (E Y Laboratories, San Mateo, Calif.) (20) , or sugar utilization tests (19) . In Baltimore and Indianapolis, isolates were tested for P-lactamase production by the chromogenic cephalosporin method, while in Seattle and Tacoma, the acidometric method was used (17) . All isolates were subcultured onto chocolate agar or supplemented GC medium base agar (Difco Laboratories, Detroit, Mich.) with the defined supplements of Kellogg et al. (8) and frozen in tryptic soy broth at -70°C for subsequent antimicrobial susceptibility testing.
Specimens for isolation of C. trachomatis were placed immediately into 0.2 M sucrose-phosphate buffer transport media and either stored at 4°C for 4 to 24 h before inoculation or stored at -70°C for up to 3 days until inoculation into cycloheximide-treated McCoy cells in microdilution wells. Growth of C. trachomatis was detected by the fluoresceinconjugated monoclonal antibody technique (Micro Trak; Syva Corp.) (6, 16) .
Antimicrobial susceptibility testing. MICs of ofloxacin, amoxicillin, penicillin G, and tetracycline HCI for N. gonorrhoeae were determined by the agar dilution technique by using GC medium base supplemented with 1% IsoVitaleX (BBL Microbiology Systems, Cockeysville, Md.) and doubling dilutions of antibiotic (14) . Gonococci with chromosomally-mediated penicillin resistance were defined on the basis of a MIC of penicillin or amoxicillin of .1 ,ug/ml if P-lactamase production was not detected. TRNG strains were identified presumptively on the basis of a tetracycline MIC of .16 ,ug/ml. RESULTS Patient population. A total of 246 patients were enrolled in the study: 40 males and 54 females in Indianapolis, 40 males ) . Consequently, data from all clinic sites were combined. Although homosexual men were not excluded, all patients enrolled were heterosexual. Efficacy. Cure rates for men and women treated with 400 mg of oral ofloxacin were 98% (47 of 48) and 100% (52 of 52), respectively. Cure rates for both men and women treated with amoxicillin-probenecid were 96% (51 of 53 men; 46 of 48 women). Overall, 99% (99 of 100) patients treated with ofloxacin and 97% (97 of 101) patients treated with amoxicillin-probenecid were cured. All 13 patients with positive rectal cultures and 7 of 8 patients with positive pharyngeal cultures treated with ofloxacin were cured, while all 17 patients with positive rectal cultures and 7 of 8 patients with positive pharyngeal cultures treated with amoxicillin-probenecid were cured (Table 1) . Combining data for all infected sites, ofloxacin eradicated infection from 99% (118 or 119) sites compared with 97% (119 of 123) sites for amoxicillin-probenecid (P values were not significant). No patients treated with ofloxacin experienced significant toxicity; one patient treated with amoxicillin plus probenecid developed transient tongue swelling.
Antimicrobial susceptibility. Of 242 pretreatment isolates, 190 were available for susceptibility testing; the remainder failed to survive storage or transport. The MIC90 of ofloxacin was 0.015 ,ug/ml (range, 0.004 to 0.125 ,ug/ml); the MIC of ofloxacin for all but two isolates was 0.03 F±g/ml or less. In contrast, the MIC90 of amoxicillin was 1.0 ,ug/ml or less. In contrast, the MIC90 of amoxicillin was 1.0 ,ug/ml (range, 0.015 to 8 ,ug/ml). Only one 3-lactamase-producing strain was isolated, but the amoxicillin MIC was -1 ,ug/ml for strains isolated from 33 patients. All 18 patients with strains for which the amoxicillin MIC was 21 ,u.g/ml who were treated with ofloxacin were cured, but 13% (2 of 15) of such patients treated with amoxicillin-probenecid had persistent infection. TRNG strains were not encountered in this study.
Effect of treatment on isolation of C. trachomatis. C. trachomatis was isolated from 15% (7 of 48) men treated with ofloxacin and 21% (11 of 53) men treated with amoxicillinprobenecid. The overall coinfection rate among men was 18% (18 of 101). After treatment, chlamydia cultures were positive in 43% (3 of 7) men treated with ofloxacin and 55% (6 of 11) men treated with amoxicillin-probenecid. Coexisting chlamydial infection in women was more common: 38% (20 of 52) of women treated with ofloxacin and 31% (15 of 48) of women treated with amoxicillin-probenecid had positive OFLOXACIN OR AMOXICILLIN-PROBENECID FOR GONORRHEA chiamydial cultures from the cervix, rectum, and/or urethra. The overall coinfection rate among women was 35% (35 of 100). After treatment, chlamydia cultures were positive in 50% (10 of 20) women treated with ofloxacin and 67% (10 of 15) women treated with amoxicillin-probenecid.
DISCUSSION
The emergence of several different forms of antibiotic resistance among gonococci and the geographic variation in prevalence of such organisms has made universal recommendations for therapy difficult (1, 3) . Since 1985, the number of reported gonococcal infections caused by PPNG in the United States has increased by more than fourfold (21) . Because the agar dilution techniques necessary for accurate antibiotic susceptibility testing have not been widely applied, the proportion of gonococcal infections caused by CMRNG and TRNG is not known. However, within 2 years of the discovery of the first outbreak in North Carolina in 1983, CMRNG strains had been isolated in 23 states (2) . Within 18 months of the first description of TRNG strains in the United States, they had been isolated in 17 states (9) . In areas where PPNG accounts for21% or CMRNG accounts for-5% of all gonococcal isolates, the Centers for Disease Control currently recommend treatment with intramuscular ceftriaxone (250 mg) (3). Although almost uniformly effective for infection at all anatomic sites, ceftriaxone is relatively expensive (approximately $7.50/250-mg dose). The necessity for intramuscular injection makes it less convenient than single-dose oral regimens.
In this study of 201 patients, ofloxacin in a single 400-mg oral dose cured 100% of urethral and cervical gonococcal infections. All 18 patients whose isolates showed at least moderate resistance to amoxicillin (MIC,-1 ,ug/ml) and who were treated with ofloxacin were cured. Only one PPNG isolate and no TRNG strains were isolated during the study. However, in this and other studies, the susceptibility and/or clinical response to ofloxacin was independent of the susceptibilities to P-lactam antibiotics or tetracycline (13, 15 In summary, ofloxacin, given as a single 400-mg dose, appears to be effective therapy for genital, and possibly rectal and pharyngeal, gonorrhea. Although the number of antibiotic-resistant strains causing infection in this study was limited, experience from other studies suggests that ofloxacin will be effective for strains expressing penicillin or tetracycline resistance or both as well.
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